Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

• ClinicalTrials.gov Identifier: NCT00555893
• Recruitment Status: Completed
• First Posted: November 9, 2007
• Results First Posted: January 14, 2015
• Last Update Posted: October 16, 2018
• Sponsor: Marshfield Clinic Research Foundation
• Collaborator: Centers for Disease Control and Prevention
• Information provided by (Responsible Party): Edward Belongia, Marshfield Clinic Research Foundation

Study Description

Brief Summary:

This study is a randomized, blinded, placebo-controlled clinical efficacy trial to assess the duration and severity of influenza symptoms, and duration of viral shedding, in influenza patients receiving oseltamivir early and late relative to placebo.

There are two main hypotheses in this study:

1. The duration of influenza symptoms, mean severity score, and duration of viral shedding are reduced in patients who initiate oseltamivir treatment late (48 to 119 hours) compared to those receiving no antiviral therapy.
2. Prior influenza vaccination (same season) reduces the duration of influenza symptoms and mean symptom severity in patients receiving oseltamivir after adjusting for age and timing of antiviral therapy (early versus late).

There are two secondary hypotheses:

1. The duration of influenza symptoms, mean severity score, and duration of viral shedding are reduced in patients with influenza who initiate oseltamivir treatment early (< 48 hours) versus late (48 to 119 hours).
2. The incidence of secondary complications is lower in patients initiating oseltamivir therapy late relative to those receiving no antiviral therapy.

Condition or disease	Intervention/treatment	Phase
Influenza	Drug: Oseltamivir; Drug: Placebo	Not Applicable

Detailed Description:

In the past decade influenza has become increasingly recognized as a serious disease and pandemic threat. Elderly persons, young children, and individuals with chronic medical conditions have the greatest risk for complications or death from influenza infection. Neuraminidase inhibitors are currently licensed for the treatment and prevention of influenza if started early in the course of illness, but little is known regarding the effects of oseltamivir (one neuraminidase inhibitor) on illness severity when initiated later in the course of illness. Greater knowledge of the treatment effects is urgently needed for optimal management of seasonal influenza, and to maximize use of a limited stockpile of antiviral drugs in the event of an influenza pandemic.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 194 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Monitoring Influenza Severity on Tamiflu (MIST)
• Study Start Date: January 2008
• Actual Primary Completion Date: February 2011
• Actual Study Completion Date: February 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active Drug; Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight: for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)	Drug: Oseltamivir; Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight: for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses); Other Name: Tamiflu
Placebo Comparator: Placebo; Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.	Drug: Placebo; Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.

Outcome Measures

Primary Outcome Measures :

1. Duration of Influenza Illness [ Time Frame: Interval (in 12 hour blocks) from time of randomization until resolution (minimum 7 days, maximum 14 days) ]
   Resolution is defined as occurring at the start of the first 24-hour period in which the total symptom score was less than or equal to 2 with no symptom rated higher than mild. Time to resolution was calculated from the time of randomization to symptom resolution in 12 hour increments.

Secondary Outcome Measures :

1. Mean Illness Severity Score [ Time Frame: Calculated from initial enrollment (randomization) up to first period of symptom resolution (minimum of 7 days, maximum of 14 days) ]
   Mean severity score will be calculated by first summing the symptom severity scores for all reporting periods from initial enrollment (randomization) up to (and including) the first period of symptom resolution, as defined above. The summed total will be divided by the number of reporting periods to yield the mean severity score for each participant. For each reporting period, the possible symptom scores will range from 0 (all symptoms absent) to 24 (all symptoms severe). For children less than 2 years old, the possible scores will range from 0 to 15.
2. Viral Shedding on Day 3-4 of Treatment [ Time Frame: 3-4 days after treatment initiation ]
   Proportion of participants with positive PCR on day 3-4 of treatment
3. Secondary Complications (Otitis Media, Sinusitis, Pneumonia, Hospital Admission) [ Time Frame: 30 days from symptom onset ]
4. Mean Influenza Well-being Score [ Time Frame: Randomization to resolution ]
   Mean influenza wellbeing score is calculated by first summing the daily scores for overall health (0-9 points), ability to perform usual activities (0-9 points), and sleep quality (0-9 points) from initial enrollment (randomization) up to (and including) the first day of symptom resolution. This is divided by the number of reporting days to yield the mean daily influenza wellbeing score for each person. Minimum score is 0 and maximum is 27. Higher scores indicate better outcome.

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 79 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

1. Outpatient or inpatient encounter for acute respiratory illness less than 5 days (120 hours) duration.
2. Acute respiratory illness with feverishness OR cough.
3. Access to the internet or telephone at home. This is required because symptom severity reports will be submitted twice daily using either a secure web-based form or automated telephone entry. All phones in the Marshfield area have touchtone service, allowing automated data entry.

Exclusion criteria:

1. Institutional resident (including assisted living or skilled nursing facility).
2. Self-reported chronic liver or kidney disease. These conditions are listed as precautions in the oseltamivir manufacturer package insert (www.rocheusa.com/products/tamiflu/pi.pdf).
3. Pregnancy or breast-feeding. Oseltamivir is classified as pregnancy category C, and it is excreted in breast milk. The package insert states that the drug should be used only if the potential benefit justifies the potential risk to the fetus or breast-fed infant.
4. Prior hypersensitivity reaction to oseltamivir.
5. Dementia, impaired communication, or other reason for inability to provide informed consent.
6. Immunocompromised status, including HIV infection, neutropenia, systemic corticosteroid use, or use of other immunosuppressive drugs in the past 30 days. The manufacturer states that the efficacy of oseltamivir has not been established in immunocompromised patients.
7. Patient received 1 or more doses of influenza antiviral agents (oseltamivir, zanamivir, amantadine, rimantadine) or a prescription for one of these drugs prior to randomization.

Contacts and Locations

Locations

United States, Wisconsin

Marshfield Clinic Research Foundation

Marshfield, Wisconsin, United States, 54449

Sponsors and Collaborators

Marshfield Clinic Research Foundation

Centers for Disease Control and Prevention

Investigators

• Principal Investigator: Edward Belongia, MD; Marshfield Clinic Research Foundation

More Information

• Responsible Party: Edward Belongia, Senior Research Scientist, Director Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield Clinic Research Foundation
• ClinicalTrials.gov Identifier: NCT00555893
• Other Study ID Numbers: 1U01IP000124-01 ( U.S. NIH Grant/Contract )
• First Posted: November 9, 2007
• Results First Posted: January 14, 2015
• Last Update Posted: October 16, 2018
• Last Verified: October 2018

Keywords provided by Edward Belongia, Marshfield Clinic Research Foundation:

randomized; blinded; controlled; efficacy

Additional relevant MeSH terms:

Influenza, Human; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Oseltamivir; Antiviral Agents; Anti-Infective Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action